- Home
- CLW vs AVTX Comparison
CLW vs AVTX Comparison
Compare CLW & AVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CLW | AVTX |
|---|---|---|
| Founded | 2005 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Paper | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 293.0M | 248.3M |
| IPO Year | N/A | 2015 |
Fundamental Metrics
Financial Performance| Metric | CLW | AVTX |
|---|---|---|
| Price | $17.96 | $17.58 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 9 |
| Target Price | $30.00 | ★ $30.14 |
| AVG Volume (30 Days) | 172.4K | ★ 376.5K |
| Earning Date | 10-28-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 875.72 | N/A |
| EPS | ★ 8.63 | N/A |
| Revenue | ★ $1,556,100,000.00 | $192,000.00 |
| Revenue This Year | $13.91 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $2.03 | ★ N/A |
| Revenue Growth | ★ 23.00 | N/A |
| 52 Week Low | $16.44 | $3.39 |
| 52 Week High | $33.57 | $19.41 |
Technical Indicators
Market Signals| Indicator | CLW | AVTX |
|---|---|---|
| Relative Strength Index (RSI) | 47.73 | 53.79 |
| Support Level | $17.39 | $15.53 |
| Resistance Level | $18.25 | $18.80 |
| Average True Range (ATR) | 0.72 | 1.52 |
| MACD | 0.11 | -0.11 |
| Stochastic Oscillator | 61.87 | 60.19 |
Price Performance
Historical ComparisonAbout CLW Clearwater Paper Corporation
Clearwater Paper Corp is engaged in the manufacturing and supplier of Solid Bleached Sulfate (SBS) paperboard packaging products. The company products includes: SBS paperboard which is a premium paperboard grade that is frequently used to produce folding cartons, food service, commercial printing items. It generates maximum revenue from Pulp and Paperboard segment. Company operate in United States and have globalized access too. Geographically, it derives maximum revenue from the United States.
About AVTX Avalo Therapeutics Inc.
Avalo Therapeutics Inc is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The company's asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).